Leadiant Biosciences, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$9.4M
Doctors Paid
333
Transactions
1,141
2024 Total
$1.3M
Payment Breakdown by Category
Research$8.8M (93.7%)
Consulting$385,122 (4.1%)
Travel$34,730 (0.4%)
Food & Beverage$14,068 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8.8M | 495 | 93.7% |
| Consulting Fee | $385,122 | 131 | 4.1% |
| Grant | $76,500 | 11 | 0.8% |
| Honoraria | $46,875 | 21 | 0.5% |
| Travel and Lodging | $34,730 | 19 | 0.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14,175 | 7 | 0.2% |
| Food and Beverage | $14,068 | 408 | 0.1% |
| Education | $7,921 | 45 | 0.1% |
| Charitable Contribution | $7,578 | 1 | 0.1% |
| Space rental or facility fees (teaching hospital only) | $4,750 | 3 | 0.1% |
Payments by Type
Research
$8.8M
495 transactions
General
$591,718
646 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| ManNAc in GNE study | $1.3M | 0 | 4 |
| Monitoring Enzyme Replacement Therapy (Registry Surveillance Study) | $1.1M | 0 | 12 |
| Safety and Efficacy of Liposomal Amphotericin B Formulations in Comparison to Natamycin (Pimaricin) and Deoxycholate Amphotericin B in Corneal Epithelial Cells and in Experimental Mycotic Keratitis | $989,121 | 0 | 7 |
| Usability Study of Cystaran Eye Drops in New Bottle in Cystinosis Subjects with Corneal Cystine Crystal Accumulation | $797,200 | 0 | 2 |
| A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy of ManNAc in Subjects with GNE Myopathy | $768,122 | 0 | 205 |
| National Institute of Health(NH0005MI)-NHGRI CRADA | $532,500 | 0 | 1 |
| National Institute of Health(NH0005MI)-08252023-NAT-INV | $455,163 | 0 | 1 |
| ANTI TUMOR EFFECTS OF LOCALLY AND SYSTEMATICALLY ADMINISTERED EZN2279 MONOTHERAPY IN A MURINE MODEL OF COLORECTAL CARCINOMA | $433,699 | 0 | 5 |
| A Study of EZN-2279 (Polyethylene Glycol Recombinant Adenosine Deaminase [PEG-rADA]) Administered as a Weekly Intramuscular Injection in Patients with Adenosine Deaminase (ADA)-Deficient Combined Immunodeficiency | $416,774 | 0 | 100 |
| Diagnosis of SCID-ADA, the biochemical monitoring of Adagen Therapy for ADA-SCID and a Demographic Analysis of the Results | $298,732 | 0 | 3 |
| The Registry Study of Revcovi Treatment in Patients With ADA-SCID | $260,291 | 0 | 3 |
| A Phase Ib/IIa Randomized, Placebo Controlled Study of the Safety and Efficacy of Once Daily Dosing of STP206 in Premature Very Low Birth Weight and Extremely Low Birth Weight Neonates | $258,704 | 0 | 43 |
| Efficacy & Safety of Aerosolized Abelcet in the Lung Transplant Population | $197,343 | 0 | 6 |
| A PHASE 1B/IIA RANDOMIZED, PLACEBO CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF ONCE DAILY DOSING OF STP206 IN PREMATURE VERY LOW BIRTH WEIGHT AND EXTREMELY LOW BIRTH WEIGHT NEONATES | $194,425 | 1 | 51 |
| Study of Adenosine-related Biomarkers in Systemic Sclerosis Patients | $168,888 | 1 | 4 |
| Reduced Burden of Oncologic Therapy in Advanced B-cell Lymphoma (REBOOT ABLY) in Children, Adolescents and Yound Adults with CD20+ Mature B-Cell Lymphoma | $115,600 | 0 | 4 |
| Prospective Cohort Study to Describe Practice Patterns and Outcomes in Pediatric Patients (Chronic Kidney Disease, Dialysis and Transplant) with Cystinosis | $57,187 | 0 | 3 |
| Single Arm, Open-Label, Multicenter, Registry Study of Revcovi (elpegademase-lvlr) Treatment in ADA-SCID Subjects Requiring Enzyme Replacement Therapy | $52,775 | 3 | 16 |
| Prospective Cohort Study to Describe Practice Patterns and Outcomes in Pediatric Patients (Chronic Kidney Disease, Dialysis, and Transplant) with Cystinosis | $44,711 | 0 | 2 |
| Effect of Carnitine on Myocardial Function in Children Receiving Continuous Renal Replacement Therapy | $41,182 | 0 | 6 |
| Determination of the role of Adenosine deaminase on Two Major Pathogenic (IFN-?+ and IL-17+) T Cell Responses | $40,349 | 0 | 1 |
| Monitoring Enzyme Replacement Therapy (Registry Surveillance Study) | $30,658 | 0 | 1 |
| NORTH AMERICAN PEDRIATRIC RENAL TRANSPLANT CASE STUDY(NO0074MI)-LeadiantCystinosis-6 | $22,356 | 0 | 1 |
| NORTH AMERICAN PEDRIATRIC RENAL TRANSPLANT CASE STUDY(NO0074MI)-LeadiantCystinosis-7 | $22,356 | 0 | 1 |
| Phase II study of the combination of high-dose methotrexate and intrathecal liposomal cytarabine | $19,320 | 0 | 1 |
| Single Arm, Open-Label, Multicenter, Registry Study of Revcovi (elpegademase-lvlr) Treatment in ADA?SCID Subjects Requiring Enzyme Replacement Therapy | $18,169 | 0 | 2 |
| Anti-Tumor Effects of locally and Systemically Administered EZN-2279 monotherapy in a murine model of Colorectal Carcinoma | $17,695 | 0 | 1 |
| Anti-tumor effects of locally and systematically administered EZN-2279 monotherapy in a murine model of Colorectal Carcinoma | $17,370 | 0 | 1 |
| A NOVEL IMMUNOTHERAPEUTIC APPROACH FOR THE TREATMENT OF MELANOMA | $17,000 | 0 | 1 |
| A Phase II Study of Punctual, Cyclic, and Intensive Chemotherapy with Liposomal Cytarabine (Depocyt) CNS Prophylaxis for Adults With Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma | $16,413 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 14
| Doctor | Specialty | Location | Total | 2017 |
|---|---|---|---|---|
| Jorge Rios-Perez, M.d, M.D | Medical Oncology | Columbus, OH | $11.90 | $0 |
| Dr. Michael Simon-Baker, M.d, M.D | Anesthesiology | Los Angeles, CA | $11.41 | $0 |
| Dr. Thomas Aung, M.d, M.D | Medical Oncology | Austin, TX | $10.96 | $0 |
| Pankaj Khemka, M.d, M.D | Infectious Disease | Anaheim, CA | $10.80 | $0 |
| Ndidiamaka Obiesie, Md, MD | Internal Medicine | Phoenix, AZ | $10.70 | $0 |
Ad
Top Products
- Revcovi $1.8M
- Cystaran $913,538
Associated Products (15)
Payment Categories
- Food & Beverage $14,068
- Consulting $385,122
- Travel & Lodging $34,730
- Research $8.8M
About Leadiant Biosciences, Inc.
Leadiant Biosciences, Inc. has made $9.4M in payments to 333 healthcare providers, recorded across 1,141 transactions in the CMS Open Payments database. In 2024, the company paid $1.3M. The top product by payment volume is Revcovi ($1.8M).
Payments were distributed across 47 medical specialties. The top specialty by payment amount is General Practice ($132,352 to 1 doctors).
Payment categories include: Food & Beverage ($14,068), Consulting ($385,122), Research ($8.8M), Travel & Lodging ($34,730).
Leadiant Biosciences, Inc. is associated with 15 products in the CMS Open Payments database, including Revcovi, Cystaran, and EZN2279.